194 related articles for article (PubMed ID: 16521183)
1. Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.
Yang YP; Ma XM; Wang CP; Han J; Lu YY; Xiang Y; Su SH; Feng YY
World J Gastroenterol; 2006 Feb; 12(5):709-15. PubMed ID: 16521183
[TBL] [Abstract][Full Text] [Related]
2. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.
Yang Y; Nemoto EM; Harvey SA; Subbotin VM; Gandhi CR
Gut; 2004 Jun; 53(6):877-83. PubMed ID: 15138217
[TBL] [Abstract][Full Text] [Related]
3. [Influence of platelet activating factor and its antagonist on portal hypertension associated with liver cirrhosis: an experiment with rats].
Wang CP; Han J; Ma XM; Dong K; Xiang Y; Su SH; Feng YY; Yang YP
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3337-41. PubMed ID: 16409839
[TBL] [Abstract][Full Text] [Related]
4. Hepatic stellate cells may be potential effectors of platelet activating factor induced portal hypertension.
Chen Y; Wang CP; Lu YY; Zhou L; Su SH; Jia HJ; Feng YY; Yang YP
World J Gastroenterol; 2008 Jan; 14(2):218-23. PubMed ID: 18186558
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of platelet-activating factor and its receptor expression in Kupffer cells in rat carbon tetrachloride-induced cirrhosis.
Lu YY; Wang CP; Zhou L; Chen Y; Su SH; Feng YY; Yang YP
World J Gastroenterol; 2008 Feb; 14(5):764-70. PubMed ID: 18205269
[TBL] [Abstract][Full Text] [Related]
6. Kupffer cells are a major source of increased platelet activating factor in the CCl4-induced cirrhotic rat liver.
Yang Y; Harvey SA; Gandhi CR
J Hepatol; 2003 Aug; 39(2):200-7. PubMed ID: 12873816
[TBL] [Abstract][Full Text] [Related]
7. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
8. Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma.
Mathonnet M; Descottes B; Valleix D; Truffinet V; Labrousse F; Denizot Y
World J Gastroenterol; 2006 May; 12(17):2773-8. PubMed ID: 16718768
[TBL] [Abstract][Full Text] [Related]
9. Identification of platelet-activating factor as the inflammatory lipid mediator in CCl4-metabolizing rat liver.
Marathe GK; Harrison KA; Roberts LJ; Morrow JD; Murphy RC; Tjoelker LW; Prescott SM; Zimmerman GA; McIntyre TM
J Lipid Res; 2001 Apr; 42(4):587-96. PubMed ID: 11290831
[TBL] [Abstract][Full Text] [Related]
10. Acute portal hypertension increases ileal vulnerability to platelet-activating factor in rats.
Sakaguchi T; Nakamura S; Suzuki S; Oda T; Ichiyama A; Baba S
J Surg Res; 1999 Sep; 86(1):116-22. PubMed ID: 10452877
[TBL] [Abstract][Full Text] [Related]
11. Role of platelet-activating factor in hepatocellular Ca2+ alterations during hemorrhagic shock.
Silomon M; Pizanis A; Larsen R; Rose S
J Surg Res; 1997 Oct; 72(2):101-6. PubMed ID: 9356229
[TBL] [Abstract][Full Text] [Related]
12. Significance of platelet activating factor receptor expression in pancreatic tissues of rats with severe acute pancreatitis and effects of BN52021.
Xia SH; Hu CX; Zhao ZL; Xia GD; Di Y
World J Gastroenterol; 2007 Jun; 13(21):2992-8. PubMed ID: 17589953
[TBL] [Abstract][Full Text] [Related]
13. Role of platelet-activating factor in leukocyte-independent plasma extravasation and mast cell activation during endotoxemia.
Walther A; Yilmaz N; Schmidt W; Bach A; Gebhard MM; Martin E; Schmidt H
J Surg Res; 2000 Oct; 93(2):265-71. PubMed ID: 11027469
[TBL] [Abstract][Full Text] [Related]
14. Role of platelet-activating factor in hepatic responses after bile duct ligation in rats.
Zhou W; Chao W; Levine BA; Olson MS
Am J Physiol; 1992 Nov; 263(5 Pt 1):G587-92. PubMed ID: 1443133
[TBL] [Abstract][Full Text] [Related]
15. Effect of platelet-activating factor (PAF) receptor antagonist (BN52021) on acetaminophen-induced acute liver injury and regeneration in rats.
Grypioti AD; Theocharis SE; Demopoulos CA; Papadopoulou-Daifoti Z; Basayiannis AC; Mykoniatis MG
Liver Int; 2006 Feb; 26(1):97-105. PubMed ID: 16420515
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
[TBL] [Abstract][Full Text] [Related]
17. Effects of the platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the liver.
Villamediana LM; Sanz E; Fernandez-Gallardo S; Caramelo C; Sanchez Crespo M; Braquet P; Lopez-Novoa JM
Life Sci; 1986 Jul; 39(3):201-5. PubMed ID: 3755490
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic effects of endotoxin and platelet activating factor in cirrhotic rats.
Kleber G; Braillon A; Gaudin C; Champigneulle B; Cailmail S; Lebrec D
Gastroenterology; 1992 Jul; 103(1):282-8. PubMed ID: 1612334
[TBL] [Abstract][Full Text] [Related]
19. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats.
Gómez-Chiarri M; Ortíz A; Lerma JL; López-Armada MJ; Mampaso F; González E; Egido J
Lab Invest; 1994 Apr; 70(4):449-59. PubMed ID: 8176885
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
